Emerging biologic drugs for the treatment of rheumatoid arthritis
- 30 November 2005
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 4 (8), 537-541
- https://doi.org/10.1016/j.autrev.2005.04.016
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisThe New England Journal of Medicine, 2004
- Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4IgThe New England Journal of Medicine, 2003
- Molecular targets in immune‐mediated diseases: the case of tumour necrosis factor and rheumatoid arthritisImmunology & Cell Biology, 2003
- Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF VariantsScience, 2003
- Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritisArthritis & Rheumatism, 2003
- Antibody therapy for rheumatoid arthritis.Current Opinion in Pharmacology, 2003
- Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletionAnnals Of The Rheumatic Diseases, 2002
- Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cellsArthritis & Rheumatism, 2002
- Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytesRheumatology, 2001
- Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphomaRheumatology, 1999